Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

ABSTRACT The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.

摘要
本研究旨在报告不可切除胶质母细胞瘤患者接受达妥昔单抗马福丁（depatuxizumab mafoditin，ABT-414）治疗后引发的眼表毒性的临床特征与转归。本研究对胶质母细胞瘤（glioblastoma multiforme）III期临床试验中接受ABT-414治疗的3例患者的眼部体征与症状进行了评估。所有患者的双眼均在首次输注ABT-414后的1周内出现损伤，均表现为轻中度角膜炎，同时伴随视力下降、视物模糊、异物感及眼部充血。上述症状与视力水平在4周后得到改善。综上，ABT-414治疗可能引发一过性眼表毒性。仅需使用人工泪液与润滑眼膏即可有效控制眼表体征与症状。临床管理该类患者需采用多学科协作模式、完善的眼科监测流程并制定专属诊疗方案，以实现合理管控。